Anita H. Clayton
Noel N. Kim
Stephanie S. Faubion
Brooke M. Faught
James A. Simon
Susan R. Davis
Murray A. Freedman
Sheryl A. Kingsberg
Lisa Larkin, Australian Catholic University
Marita McCabe, Australian Catholic University
Clayton, A. H, Goldstein, I., Kim, N. N, Althof, S., Faubion, S. S, Faught, B. M, Parish, S., Simon, J. A, Vignozzi, L., Christiansen, K., Davis, S. R, Freedman, M. A, Kingsberg, S. A, Kirana, P., Larkin, L., McCabe, M. & Sadovsky, R. (2018). The international society for the study of women's sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clinic Proceedings,93(4), L. K. Muenkel. 467-487. United Kingdom: Elsevier. Retrieved from https://doi.org/10.1016/j.mayocp.2017.11.002
The International Society for the Study of Women's Sexual Health process of care (POC) for management of hypoactive sexual desire disorder (HSDD) algorithm was developed to provide evidence-based guidelines for diagnosis and treatment of HSDD in women by health care professionals. Affecting 10% of adult females, HSDD is associated with negative emotional and psychological states and medical conditions including depression. The algorithm was developed using a modified Delphi method to reach consensus among the 17 international panelists representing multiple disciplines. The POC starts with the health care professional asking about sexual concerns, focusing on issues related to low sexual desire/interest. Diagnosis includes distinguishing between generalized acquired HSDD and other forms of low sexual interest. Biopsychosocial assessment of potentially modifiable factors facilitates initiation of treatment with education, modification of potentially modifiable factors, and, if needed, additional therapeutic intervention: sex therapy, central nervous system agents, and hormonal therapy, guided in part by menopausal status. Sex therapy includes behavior therapy, cognitive behavior therapy, and mindfulness. The only central nervous system agent currently approved by the US Food and Drug Administration (FDA) for HSDD is flibanserin in premenopausal women; use of flibanserin in postmenopausal women with HSDD is supported by data but is not FDA approved. Hormonal therapy includes off-label use of testosterone inpostmenopausal women with HSDD, which is supported by data but not FDA approved. The POC incorporates monitoring the progress of therapy. In conclusion, the International Society for the Study of Women's Sexual Health POC for the management of women with HSDD provides a rational, evidence-based guideline for health care professionals to manage patients with appropriate assessments and individualized treatments.
Institute for Health and Ageing
Open Access Journal Article
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.